Business Context and Reporting Period
Nanoviricides, Inc. filed this Form 8-K on February 1, 2013, to report the consummation of a private offering of debt securities. The company is incorporated in Nevada and maintains its principal executive offices in West Haven, Connecticut.
Key Financial Metrics and Transaction Details
- Capital Raised: $6,000,000 aggregate principal amount.
- Instrument: Unsecured 8% Coupon Series B Convertible Debentures.
- Investors: Four equity investors (private/family investment offices and a charitable foundation).
- Interest Rate: 8% per annum, payable quarterly.
- Maturity Date: January 31, 2017.
- Conversion Price: $1.00 per share of Common Stock.
- Transaction Costs: No placement agent fees or commissions were paid.
Material Changes and Terms
The filing details a material definitive agreement involving significant additional interest components beyond the standard cash coupon:
- Additional Interest (Equity): The company must issue restricted Common Stock equal to 33% of the principal amount at closing, 33% on the first anniversary, and 34% on the second anniversary.
- Additional Interest (Warrants): On the third anniversary, the company must issue warrants to purchase shares equal to 33% of the principal amount at an exercise price of $1.00.
- Redemption Rights: The company has the option to repurchase the debentures prior to maturity for the principal plus accrued interest and an additional 7% per annum, subject to issuing redemption warrants.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operations. The primary risk disclosed relates to the dilution of existing shareholders due to the conversion features and the substantial issuance of "Interest Shares" and warrants. The company agreed to use best efforts to register the shares underlying the interest and redemption warrants.
Investor Verification Checklist
- Verify the total dilution impact of the 33% equity issuance at closing and subsequent anniversaries.
- Confirm the company's ability to service the 8% cash interest payments quarterly.
- Review the company's cash position to assess the likelihood of early redemption versus conversion.
- Check for the filing of the "shelf" registration statement required for the Interest Shares and Warrants.